













Tender Reference no.-BMSIC/DRUG/17-11


S.N.	Technical Eligibility Criteria as per NIT	Firm Name - M/s IPCA Laboratories Ltd. Corporate Address: - 48, Kandivli Industrial Estate ,Kandivli (West), Mumbai-400067 Manufacturer Address:- C-6, SARA Industrial Estate, Chakrata Road,Rampur, DEhradun-248197,Uttarakhand																																																																											
1	Constitution of the Bidding Company/Firm such as Memorandum of Association and Article of Association with complete address. As per Clause 3(c).	(a) Self attested copy of cover page of Memorandum and Article of Association of IPCA Laboratories Ltd. Submitted. (Pg. No. 21-91) (b) Self attested Sanned copy of Certificate of Incorporation No.7837 dated 19/10/1949 For IPCA Laboratories Ltd. submitted. (Pg. No. 87) (c) Self attested copy of certificate for Name change from IPCA Laboratories Ltd.(Deemed public Company) to IPCA Laboratories Ltd.(full Fledged public Ltd.) is submitted Certificate No.7837 dated 07/01/1994) (Pg. No. 90) (d) Self attested copy of Fresh certificate of Incorporation on Change name From The Indian pharmaceuticals Combine Association Ltd. to IPCA Laboratories Ltd. dated 06/08/1964 issued by the Registrar of Company is submitted (page no. 88). (e) Self attested copy of Article of association submitted . (Page No. 25-78)																																																																											
2	Power of Attorney or Resolution of Board by which the authorised signatory has been authorised by bidder firm to sign the documents. As per Clause 3 (e) of the NIT.	Power of Attorney in favour of Mr. Suryakant N. Pai,General Manager-Distribution or Mr. Vijay kumar,Asstt. General Manager-Distribution duly Certified by Mr. Harish P. Kamath, Company Secretary of IPCA Laboratories Ltd., Submitted . Signature of S.N. Pai and Vijay Kumar is also attested by Mr. Harish P. Kamath . Board Resolution also submitted. (Page no.111-117)																																																																											
3	List of item Quoted in prescribed format as Annexure III as per Clause 3 (o)+B5:B6	Scanned copy of Self attested copy of list of quoted items submitted as per Annexure III where in no. of items are 4 (Four) only. (Pg. No. 14) <table><tr><th>S.N.</th><th>NIT S.N.</th><th>Name of Drug Quoted</th><th>Specification As per NIT</th><th>Pack Size</th></tr><tr><td>1</td><td>1</td><td>Chloroquin Phosphate Tablet IP 250 mg (250 mg</td><td>Chloroquin Phosphate Tablet IP 250 mg (250 mg</td><td>10's</td></tr><tr><td></td><td></td><td>Chloroquin Phos. Approx.Equiv to 155 mg Chloroq.)</td><td>Chloroquin Phos. Approx.Equiv to 155 mg Chloroq.)</td><td></td></tr><tr><td>2</td><td>7</td><td>ACT Combi pack For Different Age Group</td><td>ACT Combi pack For Different Age Group</td><td></td></tr><tr><td></td><td></td><td>Artesunate ip 50 mg + (Sulfadoxine IP 500 mg</td><td>(Artemisinin based combination Therapy or</td><td>3+1s</td></tr><tr><td></td><td></td><td>+ Pyrimethamine IP 25 mg)</td><td>Artesunate + (Sulfadoxine- + Pyrimethamine)</td><td></td></tr><tr><td></td><td></td><td>For (i) 1 to 4 year children</td><td>For (i) 1 to 4 year children</td><td></td></tr><tr><td>3</td><td>8</td><td>ACT Combi pack For Different Age Group</td><td>ACT Combi pack For Different Age Group</td><td></td></tr><tr><td></td><td></td><td>Artesunate ip 100 mg + (Sulfadoxine IP 500 mg</td><td>(Artemisinin based combination Therapy or</td><td>3+2s</td></tr><tr><td></td><td></td><td>+ Pyrimethamine ip 25 mg)</td><td>Artesunate + (Sulfadoxine- + Pyrimethamine)</td><td></td></tr><tr><td></td><td></td><td>For (i) 5 to 8 year children</td><td>For (i) 5 to 8 year children</td><td></td></tr><tr><td>4</td><td>10</td><td>ACT Combi pack For Different Age Group</td><td>ACT Combi pack For Different Age Group</td><td></td></tr><tr><td></td><td></td><td>Artesunate ip 2000+B8 mg + (Sulfadoxine IP 500 mg</td><td>(Artemisinin based combination Therapy or</td><td>3+3s</td></tr><tr><td></td><td></td><td>+ Pyrimethamine IP 25 mg)</td><td>Artesunate + (Sulfadoxine- + Pyrimethamine)</td><td></td></tr><tr><td></td><td></td><td>For (i) For 15 year and Above</td><td>For (i) For 15 year and Above</td><td></td></tr></table> Note- In annexure III, Nit Sl. No. 10 Artesunate IP 2000 mg wriiten while it should be 200 mg (In approval of product list Artesunate 200 mg written)	S.N.	NIT S.N.	Name of Drug Quoted	Specification As per NIT	Pack Size	1	1	Chloroquin Phosphate Tablet IP 250 mg (250 mg	Chloroquin Phosphate Tablet IP 250 mg (250 mg	10's			Chloroquin Phos. Approx.Equiv to 155 mg Chloroq.)	Chloroquin Phos. Approx.Equiv to 155 mg Chloroq.)		2	7	ACT Combi pack For Different Age Group	ACT Combi pack For Different Age Group				Artesunate ip 50 mg + (Sulfadoxine IP 500 mg	(Artemisinin based combination Therapy or	3+1s			+ Pyrimethamine IP 25 mg)	Artesunate + (Sulfadoxine- + Pyrimethamine)				For (i) 1 to 4 year children	For (i) 1 to 4 year children		3	8	ACT Combi pack For Different Age Group	ACT Combi pack For Different Age Group				Artesunate ip 100 mg + (Sulfadoxine IP 500 mg	(Artemisinin based combination Therapy or	3+2s			+ Pyrimethamine ip 25 mg)	Artesunate + (Sulfadoxine- + Pyrimethamine)				For (i) 5 to 8 year children	For (i) 5 to 8 year children		4	10	ACT Combi pack For Different Age Group	ACT Combi pack For Different Age Group				Artesunate ip 2000+B8 mg + (Sulfadoxine IP 500 mg	(Artemisinin based combination Therapy or	3+3s			+ Pyrimethamine IP 25 mg)	Artesunate + (Sulfadoxine- + Pyrimethamine)				For (i) For 15 year and Above	For (i) For 15 year and Above	
S.N.	NIT S.N.	Name of Drug Quoted	Specification As per NIT	Pack Size																																																																									
1	1	Chloroquin Phosphate Tablet IP 250 mg (250 mg	Chloroquin Phosphate Tablet IP 250 mg (250 mg	10's																																																																									
		Chloroquin Phos. Approx.Equiv to 155 mg Chloroq.)	Chloroquin Phos. Approx.Equiv to 155 mg Chloroq.)																																																																										
2	7	ACT Combi pack For Different Age Group	ACT Combi pack For Different Age Group																																																																										
		Artesunate ip 50 mg + (Sulfadoxine IP 500 mg	(Artemisinin based combination Therapy or	3+1s																																																																									
		+ Pyrimethamine IP 25 mg)	Artesunate + (Sulfadoxine- + Pyrimethamine)																																																																										
		For (i) 1 to 4 year children	For (i) 1 to 4 year children																																																																										
3	8	ACT Combi pack For Different Age Group	ACT Combi pack For Different Age Group																																																																										
		Artesunate ip 100 mg + (Sulfadoxine IP 500 mg	(Artemisinin based combination Therapy or	3+2s																																																																									
		+ Pyrimethamine ip 25 mg)	Artesunate + (Sulfadoxine- + Pyrimethamine)																																																																										
		For (i) 5 to 8 year children	For (i) 5 to 8 year children																																																																										
4	10	ACT Combi pack For Different Age Group	ACT Combi pack For Different Age Group																																																																										
		Artesunate ip 2000+B8 mg + (Sulfadoxine IP 500 mg	(Artemisinin based combination Therapy or	3+3s																																																																									
		+ Pyrimethamine IP 25 mg)	Artesunate + (Sulfadoxine- + Pyrimethamine)																																																																										
		For (i) For 15 year and Above	For (i) For 15 year and Above																																																																										




4	<ul style="list-style-type: none"> • Minimum three years old valid manufacturing licence of the product quoted with latest license renewal certificate. As per clause 3(f). • Approved product list as per the license issued for quoted drugs for minimum three years. As per clause 3(f). • Manufacturing License along with approved product list must be valid till the last date of the submission of tender. As per clause 3(f). • In Case of those drugs which are notified first time in IP 2014 then Manufacturing and Marketing license should be in any official compendium (USP/BP/IP) along with current valid License in IP in continuation. • Market standing certificate & Manufacturing certificate issued by the Licensing Authority as a Manufacturer for each drug quoted for the last 3 years (Certificate should be enclosed with list of items) except for the drugs falling under the category of 'New Drug' as defined by CDSCO (Central Drugs Standard Control Organization). If permission in Form 46 from DCGI has been obtained, then the 3 years Manufacturing & Market standing clause will be relaxed. • For all regulated products, the bidder should have at least two years of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCGI less than two years ago. A certificate from DCG (I) shall be required for all new regulated products to this effect. • FFS (Flow Fill & Seal Process) Technology will be accepted wherever applicable. Bidders shall submit self attested copies of required manufacturing license and approved product list in support of above mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it. As per Clause 3(f) 	<p>(a) self attested copy of original Licence No.21/UA/2006 on Form 25 and 21/UA/SC/P-2006 on Form 28 Valid from 12/04/2006 to 11/04/2011 and copy of renewal of licence on form 26 Valid from 12/04/2016 to 11/04/2021 submitted (Pg. No. 7 to 9)</p> <p>(b) self attested of Approved Product List is submitted, issued by Drugs controlling & licencing Authority, Garhwal Mandal, Uttarakhand (Page No. 3-6) Renew product List attached dated 12/04/2016.</p> <p>(c) Self attested manufacturing and Marketing certificate No. 17p/1/27/2006/12537 dated 12/09/2017 issued by Drugs Controlling and Licencing Authority (Mfg), Garwal Mandal Uttarakhand submitted valid upto 05.11.2017. Quoted product list attached with this certificate. (Page No.93-96)</p> <p>(d) Self attested manufacturing and Marketing certificate No. 17p/1/27/2006/12537 dated 12/09/2017 issued by Drugs Controlling and Licencing Authority (Mfg), Garwal Mandal Uttarakhand submitted valid upto 05.11.2017. Quoted product list attached with this certificate. (Page No.93-96)</p> <p>(e) Firm has bid for 1 to 4 year, 5 to 8 year and above 15 year child as below.</p> <table> <thead> <tr> <th>S. no.-</th><th>NIT Sr. no.</th><th>Product Detail</th></tr> </thead> <tbody> <tr> <td>1.</td><td>7 (1 to 4 year)</td><td>Artesunate Tablets Ph-Int. 50 mg & Pyrimethamine & Sulphadoxine Tablets IP (25 mg + 500 mg) Each combi blister pack contains:-3 tablets of Artesunate Tablets Ph. Int. 50 mg & 1 tablet of Primethaine & Sulphadoxine Tablets IP (25 mg + 500 mg)</td></tr> <tr> <td>2.</td><td>8 (5 to 8 year)</td><td>Artesunate Tablets Ph-Int. 100 mg & Pyrimethamine & Sulphadoxine Tablets IP (25 mg + 500 mg) Each combi blister pack contains:-3 tablets of Artesunate Tablets Ph. Int. 100 mg & 1 tablet of Primethaine & Sulphadoxine Tablets IP (25 mg + 500 mg)</td></tr> <tr> <td>3.</td><td>10 (15 years)</td><td>Artesunate Tablets Ph-Int. 200 mg & Pyrimethamine & Sulphadoxine Tablets IP (25 mg + 500 mg) Each combi blister pack contains:-3 tablets of Artesunate Tablets Ph. Int. 200 mg & 3 tablet of Primethaine & Sulphadoxine Tablets IP (25 mg + 500 mg)</td></tr> <tr> <td>4.</td><td>1</td><td>Chloroquine Phosphate Tablets IP 250 mg (equivalent to 155 mg Chloroquine base)</td></tr> </tbody> </table>	S. no.-	NIT Sr. no.	Product Detail	1.	7 (1 to 4 year)	Artesunate Tablets Ph-Int. 50 mg & Pyrimethamine & Sulphadoxine Tablets IP (25 mg + 500 mg) Each combi blister pack contains:-3 tablets of Artesunate Tablets Ph. Int. 50 mg & 1 tablet of Primethaine & Sulphadoxine Tablets IP (25 mg + 500 mg)	2.	8 (5 to 8 year)	Artesunate Tablets Ph-Int. 100 mg & Pyrimethamine & Sulphadoxine Tablets IP (25 mg + 500 mg) Each combi blister pack contains:-3 tablets of Artesunate Tablets Ph. Int. 100 mg & 1 tablet of Primethaine & Sulphadoxine Tablets IP (25 mg + 500 mg)	3.	10 (15 years)	Artesunate Tablets Ph-Int. 200 mg & Pyrimethamine & Sulphadoxine Tablets IP (25 mg + 500 mg) Each combi blister pack contains:-3 tablets of Artesunate Tablets Ph. Int. 200 mg & 3 tablet of Primethaine & Sulphadoxine Tablets IP (25 mg + 500 mg)	4.	1	Chloroquine Phosphate Tablets IP 250 mg (equivalent to 155 mg Chloroquine base)
S. no.-	NIT Sr. no.	Product Detail															
1.	7 (1 to 4 year)	Artesunate Tablets Ph-Int. 50 mg & Pyrimethamine & Sulphadoxine Tablets IP (25 mg + 500 mg) Each combi blister pack contains:-3 tablets of Artesunate Tablets Ph. Int. 50 mg & 1 tablet of Primethaine & Sulphadoxine Tablets IP (25 mg + 500 mg)															
2.	8 (5 to 8 year)	Artesunate Tablets Ph-Int. 100 mg & Pyrimethamine & Sulphadoxine Tablets IP (25 mg + 500 mg) Each combi blister pack contains:-3 tablets of Artesunate Tablets Ph. Int. 100 mg & 1 tablet of Primethaine & Sulphadoxine Tablets IP (25 mg + 500 mg)															
3.	10 (15 years)	Artesunate Tablets Ph-Int. 200 mg & Pyrimethamine & Sulphadoxine Tablets IP (25 mg + 500 mg) Each combi blister pack contains:-3 tablets of Artesunate Tablets Ph. Int. 200 mg & 3 tablet of Primethaine & Sulphadoxine Tablets IP (25 mg + 500 mg)															
4.	1	Chloroquine Phosphate Tablets IP 250 mg (equivalent to 155 mg Chloroquine base)															
5	In case of Importer, the bidder (importer) firm must have minimum three years old valid import License of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product are being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender. As per Clause 3(g)	Import Licence for the quoted products not applicable (Page No.100)															
6	Self attested copies of Market standing certificate (in India) of minimum three years, issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. As per Clause 3(h)	Self attested manufacturing and Marketing certificate No. 17p/1/27/2006/12537 dated 12/09/2017 issued by Drugs Controlling and Licencing Authority (Mfg), Garwal Mandal Uttarakhand submitted valid upto 05.11.2017. Quoted product list attached with this certificate. (Page No.93-96)															
7	Self attested copy of Non Conviction Certificate (NCC), issued by the concerned Licensing Authority from Drug Control Administration of the state for last three years. It should be not more than one year old. As per Clause 3(i).	Self attested copy of No Conviction certificate bearing no. 17p/1/27/2006/8861, dated 06/07/2017 issued by Drugs Controlling and Licencing Authority (Mfg), Garwal Mandal Uttarakhand submitted valid upto 05.11.2017 (Pg. No. 18)															

8	Self attested copies of WHO-GMP/GMP as per revised Schedule- 'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority / Drugs Control Department. The GMP certificate must not be older than one year from the last date of submission of tender. As per clause 3(j).	(a) Self attested copy of GMP certificate dated 04/08/2016 Valid till 03/08/2018 for Tablet and Capsule section (Non-Betalactum) issued by the Drugs Licensing & controlling Authority, Uttarakhand submitted . The certificate No. 17P/1/27/2006/ 0285 is issued for Licence No. 21/UA/2006 (on form 25), 21/UA/SC/P-2006 (on form 28) and 121/UA/X/2007. (Page No. 1-2)		
9	Self attested copies of Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority form Drugs Control Department highlighting the quoted product section.In case of Importer An affidavit (With Stamp) sworn before first class magistrate/Notary stating the batch production capacity of the firm and also that said production (Importing)capacity shall be adequate for requirement laid in NIT. Importers will have also to submit Invoices/Evidence of import in items of said product with quantity details. As per Clause 3(k).	Self attested copy of Maximum Production Capacity certificate No. 17p/1/27/2006/ 2323 dated 01/09/2016 Submitted,issued by Drugs Controlling & Licencing Authority (mfg.) , Garhwal Mandal ,Uttarakhand. According to certificate Maximum capacity issued for Tablet and Capsule section for IPCA Laboratories Ltd. bearing Licence No.21/UA/2006 (on form 25), 21/UA/SC?P-2006 (on form 28) and 121/UA/X/2007 (on form 25F) Valid Till 05/11/2017. (Page No.92)		
10	An affidavit (with stamp)sworn before first class magistrate/Notary stating that the firm & its quoted product is not black listed currently (as on the last date of submission of the tender) by Central Government/ Central Government Agencies/any state government/any of the state government agencies/any Drug Procurement Agencies or by BMSICL as per Annexure II (clause 3(n) of NIT).	Self attested copy of Notarised affidavit on Rs.100/- non Judicial stamp paper Submitted along with List of quoted products. Party written that firm and its quoted products not blacklisted as per our annexure No.II. (Page No. 16-17)		
11	EMD details (DD number/BG number and date with issuing bank) as per Clause 3(b) .	EMD by Kotak Mahindra Bank BG No. "0958OBG17017843" dt.12/10/2017 for Rs. 2,00,000/- submitted (Page No-101-105)		
12	Tender Fee Rs 10,000/- in form of DD as per Clause 3(a).	Tender fee by DD NO "550182" dt. 12/10/2017 for Rs. 10,000/- submitted (Page No-11)		
13	Self attested copies of the Audited Annual Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than 25 crores for any three of the last four consecutive financial years. (Auditor/ C.A. Certificate of turnover will not be accepted). As per Clause 3(l)	FY-2013-14	Rs.3,266.86 (in crore)	Page No-117
		FY -2014-15	Rs.3,116.94 (in crore)	Page No -117
		FY -2015-16	Rs.2,847.61(in crore)	Page No:- 121
		FY -2016-17	Rs.3,156.66(in crore)	Page No - 123
14	Self attested copy of Income Tax Return for any three of last four consecutive Assessment years. As per Clause 3(m).	FY-2016-2017		Page No-99
		FY-2015-2016		Page No-98
		FY-2014-2015		Page No-97
15	Self attested copy of PAN Card of the Bidder Company. As per Clause 3(p)	PAN No -"AAACI1220M"		Page No-15
16	Self attested copy of Certificate of valid Sales tax/VAT registration of the bidder company. As per Clause 3(q)	GSTIN No-" 10AAACI1220M1Z8"		Page No-106-107
		TIN No-" 27510370644V"		Page No-108
		Central) " 27510370644C"		Page No-109
17	Affidavit (with stamp)declaration regarding acceptance of tender conditions to be submitted by the bidding firm as per Annexure IV (Clause 5(k) of NIT).	Self attested Notarised affidavit on Rs.100/- non judicial stamp paper by Mr. S.N. Pai for Acceptance of tender condition as per Annexure IV is submitted. (Pg. No. 12-13)		



The facts in clause No-1 to 10 and 17 of the provided sheet has been compiled with due diligence and care, on the basis of document provided by BMSICL, in compliance of letter No 1146(15) Dt-05.11.2016 of Health Department, Govt of Bihar . Inspite, some inadvertent discrepancies could have been crept in. Humble request to all concerned to bring to notice in due time if any discrepancies is observed for rectification.

mit Hm ~~B~~ Lipinski TH Auswahl RD Bel AS
(11/16)